Rafael Holdings, Inc. (RFL) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended October 31, 2024 (Fiscal Q1 2025). Rafael Holdings, Inc. is a holding company focused on clinical and early-stage pharmaceutical investments. The company's primary strategic focus is a planned merger with Cyclo Therapeutics Inc. (CYTH), a clinical-stage biotechnology company developing Trappsol® Cyclo™ for Niemann-Pick Disease Type C1. Other portfolio assets include Cornerstone Pharmaceuticals (acquired March 2024), Day Three Labs (acquired January 2024), LipoMedix, and a real estate asset in Jerusalem.
Key Financial Metrics
| Metric | Q1 2025 (Oct 31, 2024) | Q1 2024 (Oct 31, 2023) |
|---|---|---|
| Total Revenue | $128,000 | $68,000 |
| Net Loss (Consolidated) | $(9,211,000) | $(3,760,000) |
| Net Loss Attributable to RFL | $(9,006,000) | $(3,638,000) |
| Loss Per Share (Basic & Diluted) | $(0.37) | $(0.15) |
| Cash and Cash Equivalents | $8,159,000 | $13,197,000 |
| Available-for-Sale Securities | $46,138,000 | $63,265,000 |
| Total Assets | $87,835,000 | $96,832,000 |
| Working Capital | $63,242,000 | $64,988,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 88% to $128,000, driven by the consolidation of Day Three Labs (Infusion Technology segment), which generated $51,000 in revenue. Real Estate revenue remained stable at $77,000.
- Increased Net Loss: Net loss widened significantly to $9.2 million from $3.8 million. This was primarily due to:
- Unrealized Investment Losses: A $4.4 million unrealized loss on the Cyclo Therapeutics investment and a $1.6 million unrealized loss on convertible notes receivable due from Cyclo, attributed to declines in Cyclo's stock price.
- Operating Expenses: Operating expenses increased due to the inclusion of Cornerstone Pharmaceuticals following its March 2024 acquisition and higher professional fees related to the Cyclo merger.
- Investment Portfolio Shift: The company sold a portion of its available-for-sale securities, reducing the balance from $63.3 million to $46.1 million, while increasing cash holdings.
Guidance, Outlook, and Risks
- Merger with Cyclo: On August 21, 2024, Rafael entered into a Merger Agreement with Cyclo. The transaction is expected to close in Q1 2025, subject to shareholder approval. Upon closing, Rafael intends to fund Cyclo's Phase 3 clinical trial (TransportNPC) to its interim analysis in mid-2025.
- Funding Commitment: Rafael has committed to funding Cyclo's operations pre-closing and up to $25 million post-closing for the clinical trial.
- Subsequent Events: In November and December 2024, Rafael issued an additional $3 million in convertible notes to Cyclo. In November 2024, the company sold its remaining available-for-sale securities for $52.9 million to reallocate assets for the merger.
- Liquidity: Management expects current cash and securities to be sufficient to meet obligations for at least the next 12 months.
- Risks: Key risks include the failure of the Cyclo merger to close, continued volatility in the fair value of Cyclo investments, and the success of clinical trials for portfolio companies.
Investor Verification Checklist
- Merger Status: Verify the progress of shareholder approvals for the Cyclo Therapeutics merger and the expected closing date.
- Investment Valuation: Review the fair value methodology for Cyclo common stock and convertible notes, as unrealized losses significantly impacted the P&L.
- Cash Burn Rate: Assess the impact of the $25 million funding commitment for Cyclo's clinical trial on future liquidity.
- Cornerstone Integration: Monitor the operational direction and resource allocation for Cornerstone Pharmaceuticals following its acquisition.
- Subsequent Sales: Confirm the impact of the November 2024 sale of available-for-sale securities on the balance sheet in the next filing.